MCID: CRB059
MIFTS: 34

Cerebellar Degeneration malady

Categories: Rare diseases, Neuronal diseases, Metabolic diseases

Aliases & Classifications for Cerebellar Degeneration

Aliases & Descriptions for Cerebellar Degeneration:

Name: Cerebellar Degeneration 50 51 52 69

Classifications:



Summaries for Cerebellar Degeneration

NIH Rare Diseases : 50 cerebellar degeneration refers to the deterioration of neurons (nerve cells) in the cerebellum (the area of the brain that controls muscle coordination and balance). conditions that cause cerebellar degeneration may also affect other areas of the central nervous system, such as the spinal cord, the cerebral cortex (the thin layer of cells covering the brain), and the brain stem. signs and symptoms of cerebellar degeneration may include a wide-based, uncoordinated walk; a back and forth tremor in the trunk of the body; uncoordinated movements of the arms and legs; slow and slurred speech; and nystagmus. cerebellar degeneration can be caused by a variety of factors including inherited gene changes (mutations), chronic alcohol abuse, and paraneoplastic disorders. treatment for cerebellar degeneration varies depending on the underlying cause. last updated: 12/14/2014

MalaCards based summary : Cerebellar Degeneration is related to subacute cerebellar degeneration and paraneoplastic cerebellar degeneration. An important gene associated with Cerebellar Degeneration is CDR1 (Cerebellar Degeneration Related Protein 1). The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and cerebellum, and related phenotype is Decreased ionizing radiation sensitivity.

NINDS : 51 Cerebellar degeneration is a process in which neurons in the cerebellum - the area of the brain that controls coordination and balance - deteriorate and die. Diseases that cause cerebellar degeneration can also involve other areas of the central nervous system,including the spinal cord, medulla oblongata, cerebral cortex, and brain stem. Cerebellar degeneration may be the result of inherited genetic mutations that alter the normal production of specific proteins that are necessary for the survival of neurons.

Related Diseases for Cerebellar Degeneration

Diseases in the Cerebellar Degeneration family:

Primary Cerebellar Degeneration Subacute Cerebellar Degeneration

Diseases related to Cerebellar Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
id Related Disease Score Top Affiliating Genes
1 subacute cerebellar degeneration 12.3
2 paraneoplastic cerebellar degeneration 12.3
3 primary cerebellar degeneration 12.0
4 ichthyosis, hepatosplenomegaly, and cerebellar degeneration 12.0
5 paraneoplastic syndromes 11.0
6 ataxia-telangiectasia-like disorder 11.0
7 infantile cerebellar-retinal degeneration 10.8
8 spinocerebellar ataxia 2 10.8
9 dykes markes harper syndrome 10.8
10 menkes disease 10.7
11 paraneoplastic neurologic disorders 10.7
12 familial hemiplegic migraine 10.7
13 neuronitis 10.1
14 ataxia 10.1
15 adenocarcinoma 10.1
16 lymphoma 10.1
17 lambert-eaton myasthenic syndrome 10.1
18 ovarian cancer 10.0
19 breast cancer 10.0
20 lung cancer 10.0
21 substance-induced psychosis 10.0 ATM CACNA1A
22 prostatitis 9.9
23 tremor 9.9
24 encephalitis 9.8
25 limbic encephalitis 9.8
26 hodgkin lymphoma 9.8
27 hermansky-pudlak syndrome 3 9.8 CA8 CACNA1A
28 squamous cell carcinoma 9.8
29 neuropathy 9.8
30 prostate adenocarcinoma 9.8
31 lambert syndrome 9.8
32 neuroleptic malignant syndrome 9.8
33 b-cell lymphomas 9.7
34 spasticity 9.7
35 merkel cell carcinoma 9.7
36 ataxia-telangiectasia 9.7
37 diffuse large b-cell lymphoma 9.7
38 hypogonadism 9.7
39 endometrial cancer 9.7
40 neuroaxonal dystrophy 9.7
41 nephrotic syndrome 9.7
42 severe combined immunodeficiency 9.7
43 dementia 9.7
44 paraplegia 9.7
45 diarrhea 9.7
46 cerebritis 9.7
47 cerebellar ataxia 9.7
48 retinitis 9.7
49 ichthyosis 9.7
50 fallopian tube adenocarcinoma 9.7

Graphical network of the top 20 diseases related to Cerebellar Degeneration:



Diseases related to Cerebellar Degeneration

Symptoms & Phenotypes for Cerebellar Degeneration

GenomeRNAi Phenotypes related to Cerebellar Degeneration according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased ionizing radiation sensitivity GR00232-A-1 8.92 ATM CA8 CDR1 ZIC1

Drugs & Therapeutics for Cerebellar Degeneration

Drugs for Cerebellar Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 1,Phase 2 51-61-6, 62-31-7 681
2
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
3
Citalopram Approved Phase 4 59729-33-8 2771
4
Serotonin Phase 4 50-67-9 5202
5 Muscarinic Antagonists Phase 4
6 Cholinergic Agents Phase 4,Phase 2,Phase 3
7 Cholinergic Antagonists Phase 4
8 Serotonin Agents Phase 4
9 Serotonin Uptake Inhibitors Phase 4
10 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
11 Neurotransmitter Uptake Inhibitors Phase 4
12 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Parasympatholytics Phase 4
15 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2,Early Phase 1
16 Dopamine Agents Phase 4,Phase 1,Phase 2
17 Dopamine Uptake Inhibitors Phase 4
18 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Antidepressive Agents, Second-Generation Phase 4
20 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
21 Autonomic Agents Phase 4,Early Phase 1
22 Antiparkinson Agents Phase 4
23
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
24
Riluzole Approved, Investigational Phase 2, Phase 3 1744-22-5 5070
25 Idebenone Approved, Investigational Phase 3,Phase 2,Phase 1 58186-27-9
26
Varenicline Approved, Investigational Phase 2, Phase 3 249296-44-4 5310966
27 Ubiquinone Phase 3,Phase 2,Phase 1
28 calcitonin Phase 3,Phase 2
29 Lithium carbonate Phase 2, Phase 3,Phase 1 554-13-2
30 interferons Phase 3,Phase 2
31 Neuroprotective Agents Phase 2, Phase 3,Early Phase 1
32 Thyrotropin-Releasing Hormone Phase 3,Phase 2
33 Nicotinic Agonists Phase 2, Phase 3
34 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
35 Trace Elements Phase 3,Phase 2,Phase 1
36 Hormone Antagonists Phase 3,Phase 2,Early Phase 1
37 Tranquilizing Agents Phase 2, Phase 3,Phase 1
38 Hormones Phase 3,Phase 2,Early Phase 1
39 Vaccines Phase 3
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Early Phase 1
41 Hypoglycemic Agents Phase 3
42 Excitatory Amino Acid Antagonists Phase 2, Phase 3
43 Excitatory Amino Acids Phase 2, Phase 3
44 Anti-Infective Agents Phase 3,Phase 2
45 Anticonvulsants Phase 2, Phase 3
46 Protective Agents Phase 2, Phase 3, Phase 1, Early Phase 1
47 Interferon-gamma Phase 3,Phase 2
48 Antimanic Agents Phase 2, Phase 3,Phase 1
49 Micronutrients Phase 3,Phase 2,Phase 1
50 Antiviral Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 108)
id Name Status NCT ID Phase
1 An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia Completed NCT01716221 Phase 4
2 An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970111 Phase 3
3 A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970098 Phase 3
4 Efficacy of Riluzole in Hereditary Cerebellar Ataxia Completed NCT01104649 Phase 2, Phase 3
5 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3
6 A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970124 Phase 3
7 A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01970137 Phase 3
8 Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 Completed NCT01096082 Phase 2, Phase 3
9 Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia Study Completed NCT02593773 Phase 3
10 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Completed NCT02415127 Phase 3
11 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Completed NCT01303406 Phase 3
12 Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension) Completed NCT00993967 Phase 3
13 A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients Completed NCT00905268 Phase 3
14 Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept Completed NCT00811681 Phase 3
15 Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Completed NCT00697073 Phase 3
16 Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Completed NCT00537680 Phase 3
17 STEADFAST Long-Term Safety Extension Completed NCT02797080 Phase 3
18 An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Recruiting NCT02889302 Phase 3
19 Trial in Adult Subjects With Spinocerebellar Ataxia Recruiting NCT02960893 Phase 2, Phase 3
20 Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia Terminated NCT00803868 Phase 2, Phase 3
21 A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation Unknown status NCT01489267 Phase 2
22 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia Unknown status NCT01360164 Phase 1, Phase 2
23 The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease Unknown status NCT02039206 Phase 2
24 High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration Completed NCT00034242 Phase 2
25 Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 Completed NCT00992771 Phase 2
26 A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET) Completed NCT01503944 Phase 1, Phase 2
27 Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia Completed NCT00202397 Phase 2
28 A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01004016 Phase 2
29 Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT00863538 Phase 2
30 A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Completed NCT01384435 Phase 2
31 Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia Completed NCT01350440 Phase 2
32 Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2) Completed NCT00998634 Phase 2
33 Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease Completed NCT02147886 Phase 2
34 A First in Human Study of RT001 in Patients With Friedreich's Ataxia Completed NCT02445794 Phase 1, Phase 2
35 A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients Completed NCT02035020 Phase 2
36 Interferon Gamma-1b in Friedreich Ataxia (FRDA) Completed NCT01965327 Phase 2
37 EPI-743 in Friedreich's Ataxia Point Mutations Completed NCT01962363 Phase 2
38 Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia Completed NCT01728064 Phase 2
39 Efficacy Study of Epoetin Alfa in Friedreich Ataxia Completed NCT01493973 Phase 2
40 A Study of Resveratrol as Treatment for Friedreich Ataxia Completed NCT01339884 Phase 1, Phase 2
41 Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Completed NCT01035671 Phase 2
42 Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia Completed NCT01016366 Phase 2
43 A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia Completed NCT00897221 Phase 2
44 Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia Completed NCT00824512 Phase 2
45 Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia Completed NCT00631202 Phase 2
46 A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia Completed NCT00530127 Phase 1, Phase 2
47 Idebenone to Treat Friedreich's Ataxia Completed NCT00229632 Phase 2
48 Iron-Chelating Therapy and Friedreich Ataxia Completed NCT00224640 Phase 1, Phase 2
49 Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia Recruiting NCT02540655 Phase 2
50 RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe Recruiting NCT02255435 Phase 2

Search NIH Clinical Center for Cerebellar Degeneration

Genetic Tests for Cerebellar Degeneration

Anatomical Context for Cerebellar Degeneration

MalaCards organs/tissues related to Cerebellar Degeneration:

39
Brain, Cortex, Cerebellum, Spinal Cord, Lung, Breast, Medulla Oblongata

Publications for Cerebellar Degeneration

Articles related to Cerebellar Degeneration:

(show top 50) (show all 553)
id Title Authors Year
1
Paraneoplastic Cerebellar Degeneration Associated with Pelvic Liposarcoma: A Rare Case Report. ( 28092914 )
2017
2
Anti-Yo positive paraneoplastic cerebellar degeneration in the setting of cholangiocarcinoma. ( 27816258 )
2017
3
Structural cerebellar correlates of cognitive and motor dysfunctions in cerebellar degeneration. ( 28043955 )
2017
4
Adult Onset Sporadic Cerebellar Ataxia in Singapore: Diagnostic Outcomes of Paraneoplastic Antibody Testing and Early Clinical Features of Paraneoplastic Cerebellar Degeneration. ( 28417137 )
2017
5
CAG repeat length does not associate with the rate of cerebellar degeneration in spinocerebellar ataxia type 3. ( 27942452 )
2017
6
Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. ( 27957508 )
2017
7
Paraneoplastic cerebellar degeneration and endometrial cancer: a rare occurrence. ( 27020505 )
2016
8
Population-based study of alcoholic cerebellar degeneration: The Atahualpa Project. ( 27423619 )
2016
9
Hodgkin's lymphoma associated with paraneoplastic cerebellar degeneration in children: a case report and review of the literature. ( 27796550 )
2016
10
Anti-Ri antibody-mediated paraneoplastic cerebellar degeneration: A rare, treatable yet poorly recognized entity. ( 27625249 )
2016
11
Secondary orthostatic tremor in the setting of cerebellar degeneration. ( 26765757 )
2016
12
Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. ( 27606347 )
2016
13
Restoring Balance: Paraneoplastic Cerebellar Degeneration. ( 27816447 )
2016
14
Paraneoplastic Cerebellar Degeneration-A Rare Presentation of Ovarian Malignancy. ( 27803545 )
2016
15
Genetic and pharmacological evidence implicates cathepsins in Niemann-Pick C cerebellar degeneration. ( 26908626 )
2016
16
Voltage-gated calcium channel autoimmune cerebellar degeneration: Case and study of cytotoxicity. ( 27088118 )
2016
17
Multiple System Atrophy Mistaken for Autoimmune Cerebellar Degeneration. ( 27107926 )
2016
18
A case of slowly progressive anti-Yo-associated paraneoplastic cerebellar degeneration successfully treated with antitumor and immunotherapy. ( 27356731 )
2016
19
Paraneoplastic cerebellar degeneration as a marker of endometrial cancer recurrence. ( 27194676 )
2016
20
Smaller Absolute Quantities but Greater Relative Densities of Microvessels Are Associated with Cerebellar Degeneration in Lurcher Mice. ( 27147979 )
2016
21
Alcohol-related cerebellar degeneration: not all down to toxicity? ( 27729985 )
2016
22
An uncommon manifestation of paraneoplastic cerebellar degeneration in a patient with high grade urothelial, carcinoma with squamous differentiation: A case report and literature review. ( 27209351 )
2016
23
Progressive cerebellar degeneration revealing Primary SjAPgren Syndrome: a case report. ( 27777786 )
2016
24
Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenia in a patient with Merkel cell carcinoma and voltage-gated calcium channel antibodies. ( 28006860 )
2016
25
Autoimmune neurological syndromes associated limbic encephalitis and paraneoplastic cerebellar degeneration. ( 27592059 )
2016
26
Voltage-Gated P/Q-Type Calcium Channel Antibodies Associated With Cerebellar Degeneration. ( 27436538 )
2016
27
Years of Drinking but Not the Amount of Alcohol Intake Contribute to the Association Between Alcoholic Cerebellar Degeneration and Worse Cognitive Performance. A Population-Based Study. ( 27696290 )
2016
28
Early-stage Alcoholic Cerebellar Degeneration: Diagnostic Imaging Clues. ( 26848494 )
2015
29
Anti-yo antibody uptake and interaction with its intracellular target antigen causes purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers. ( 25885452 )
2015
30
A Rare Case of Ovarian Cancer Presenting with Paraneoplastic Cerebellar Degeneration and Limbic Encephalitis. ( 26415811 )
2015
31
Cerebellar Degeneration as a Rare Paraneoplastic Syndrome in a Child With Hodgkin Lymphoma. ( 26599987 )
2015
32
Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. ( 25745634 )
2015
33
Rapid Onset of Motor Deficits in a Mouse Model of Spinocerebellar Ataxia Type 6 Precedes Late Cerebellar Degeneration. ( 26730403 )
2015
34
Paraneoplastic cerebellar degeneration as an early sign of classical Hodgkin lymphoma. ( 26542148 )
2015
35
Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus. ( 25753172 )
2015
36
The Effect of Cerebellar Degeneration on Human Sensori-motor Plasticity. ( 26140957 )
2015
37
Deletion of Inpp5a causes ataxia and cerebellar degeneration in mice. ( 26051944 )
2015
38
Paraneoplastic cerebellar degeneration with anti-CV2/CRMP5 antibodies and prostate adenocarcinoma. ( 25686614 )
2015
39
Paraneoplastic cerebellar degeneration in a patient with ovarian cancer. ( 26166348 )
2015
40
Dystonia and cerebellar degeneration in the leaner mouse mutant. ( 25791619 )
2015
41
Rapid Eye Movement-Sleep Behavior Disorder in Paraneoplastic Cerebellar Degeneration: Improvement with Immunotherapy. ( 26414894 )
2015
42
Ataxin-3, DNA damage repair, and SCA3 cerebellar degeneration: on the path to parsimony? ( 25633989 )
2015
43
Gaze holding deficits discriminate early from late onset cerebellar degeneration. ( 25980905 )
2015
44
Modulation of error-sensitivity during a prism adaptation task in people with cerebellar degeneration. ( 26311179 )
2015
45
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. ( 26694863 )
2015
46
Plasticity-related gene 5: A novel surface autoantigen in paraneoplastic cerebellar degeneration. ( 26445730 )
2015
47
Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease. ( 26048156 )
2015
48
JC virus granule cell neuronopathy: A cause of infectious cerebellar degeneration. ( 26003226 )
2015
49
Diagnosis of Dual Malignancy by 18F-FDG-PET/CT in the setting of Paraneoplastic Cerebellar Degeneration. ( 26271804 )
2015
50
Paraneoplastic cerebellar degeneration and dermatomyositis as first manifestations of underlying breast malignancy: a report of two cases and a brief review of the subject. ( 26366356 )
2015

Variations for Cerebellar Degeneration

Expression for Cerebellar Degeneration

Search GEO for disease gene expression data for Cerebellar Degeneration.

Pathways for Cerebellar Degeneration

GO Terms for Cerebellar Degeneration

Biological processes related to Cerebellar Degeneration according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 adult walking behavior GO:0007628 8.62 CACNA1A ZIC1

Sources for Cerebellar Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....